Privo Technologies, Inc. Announces Positive Results From Phase 1/2 Clinical Trial for PRV111 in Head and Neck Squamous Cell Carcinoma PEABODY, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Privo Technologies, Inc. ("Privo"), announced today the positive results of their Phase 1/2 clinical trial examining their lead asset PRV111 in...